Citing the need to prove that direct-to-consumer genetic assays are analytically and clinically accurate, CDRH sent letters to five genetic testing firms June 10 requesting pre-market submissions for the companies' already-marketed services
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
